Today we're bringing you an article out of Forbes Health where contributing author, Steve Brozak weighs in on the status of the Affordable Care Act. The article highlights the recent failure of the bill and what he believes the House should plan to present during the next go-around, if the opportunity arises.
Brozak comments, "What was missing from the conversation, however, was an assessment of
how the AHCA could also adversely affect revenue generation within the
biotechnology and pharmaceutical industries. While the legislation did
not specifically address drug manufacturers–Republicans had hoped to
deal with this issue of drug pricing in their third tranche of
healthcare reform–many of the largest biopharmaceutical firms would have
been impacted directly through changes within the Medicaid system and
the projected loss of up to 15 million beneficiaries by 2026."
This is an interesting read that we encourage you to take a closer at. Find the full article HERE!
HORIZON
Health Ventures is a healthcare cost management solutions company used
by insurance brokers, employee benefit consultants, third-party
administrators, insurance companies, and associations, to bring proven
thought leadership and strategy to the management of their clients
healthcare costs. To learn more about HHV and their services, please
visit http://horizonhealthventures.com/
No comments:
Post a Comment